1800 202 8726
Molecular testing

EGFR Testing in — Lung Cancer

EGFR testing is the single most consequential molecular test in Indian lung cancer care. It finds a specific mutation in your tumour that determines whether a class of targeted therapy is an option for you — and the answer changes your entire treatment plan.

Medically reviewed by Dr. Muralidhar Muddusetty, Surgical Oncologist, MBBS (AIIMS) · MS Surgery (AIIMS) · DNB Surg Onc · MRCS (Edinburgh) · Last reviewed September 2026

  • Determines targeted therapy eligibility — A positive result means a class of targeted oral therapy may be more effective for your cancer than chemotherapy.
  • Especially relevant in India — EGFR mutations occur in Indian patients at substantially higher rates than in Western populations.
  • Done on existing biopsy tissue — In most cases, no new procedure is needed — the laboratory tests the sample already taken.
  • A blood test is an alternative — If tissue is insufficient, a liquid biopsy from a blood draw can detect EGFR mutations.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Get this explained properly

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Report reviewed by a senior oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

EGFR testing looks for specific mutations in your lung cancer cells. When a mutation is found, it means a class of targeted therapy may work for your cancer instead of chemotherapy. NCCN, ASCO and ESMO all recommend EGFR testing for every patient diagnosed with non-small cell lung cancer.

Tissue biopsy or blood test: which is used for EGFR testing?

Tissue biopsyLiquid biopsy (blood test)
What is analysedTumour cells from your biopsy sampleCancer DNA fragments circulating in your blood
When it is usedFirst choice when biopsy tissue is availableWhen tissue is too small, or for repeat testing after progression
Time to resultUsually one to two weeksUsually one to two weeks
Main limitationRequires an adequate biopsy sampleMay miss mutations when tumour DNA in blood is very low
Guideline statusPreferred — NCCN and ESMOAcceptable alternative — NCCN and ESMO

What should I check with my team before my EGFR result?

  • Confirm testing has been orderedAsk your oncologist directly whether EGFR testing is included in your diagnostic workup.
  • Keep a copy of your pathology reportThe testing laboratory may need it to confirm the tumour type they are analysing.
  • Ask about a blood test if the biopsy sample was smallA liquid biopsy is an established alternative when tumour tissue is insufficient.
  • Ask when results are expectedResults usually take one to two weeks. Get a date so you are not waiting without a timeline.
  • Tell your team about any prior targeted therapyPrevious treatment changes which mutations are most relevant and affects what is tested.

What does a positive EGFR result actually change?

A positive result means your cancer has a mutation that a class of targeted therapy is specifically designed to block. Your oncologist will use this finding to recommend targeted therapy instead of, or alongside, chemotherapy.

Targeted therapy for EGFR-mutated lung cancer is taken as a daily oral tablet. It is generally given as day care, without the infusion schedule that chemotherapy requires.

The mutation subtype matters. Some mutations predict a strong initial response. Others — particularly one called T790M — appear when resistance develops and guide what to try next. Your oncologist decides which approach fits your mutation, your stage, your fitness, and your treatment history.

Still unclear?

Send your reports across and a specialist will walk you through what they mean — what is known, what is not, and what the options actually are.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Get a straight answer from a specialist

45 minutes, your reports reviewed, your questions answered in plain language.

Book Free Consultation Call 1800 202 8726

What do the terms on your EGFR report mean?

EGFR
Epidermal growth factor receptor — a protein that controls cell growth. When the gene encoding this protein is mutated in cancer cells, it can drive uncontrolled division.
Sensitizing mutation
A change in the EGFR gene that makes the cancer likely to respond to targeted therapy. The two most common are the exon 19 deletion and the exon 21 L858R substitution.
Exon 19 deletion
The most common EGFR sensitizing mutation. A short stretch of genetic code is absent, and the cancer is generally responsive to first-line targeted therapy.
Exon 21 L858R
The second most common sensitizing mutation. A single letter in the genetic code is changed at one specific location, with broadly similar treatment implications to exon 19 deletion.
T790M
A resistance mutation that often appears when cancer progresses after targeted therapy. Repeat EGFR testing at that point specifically looks for T790M to guide the next decision.
Liquid biopsy
A blood test that detects cancer DNA circulating in the bloodstream, used when tumour tissue is unavailable or insufficient for standard testing.
ctDNA
Circulating tumour DNA — fragments of cancer cell genetic material shed into the blood. This is what a liquid biopsy detects and analyses.

What happens when no EGFR mutation is found?

A negative result is still useful. It tells your oncologist that EGFR-targeted therapy is unlikely to help, and that other paths should be explored.

For most patients with non-small cell lung cancer, a negative EGFR result leads directly to testing for other actionable mutations — including ALK, ROS1 and KRAS — and assessment of PD-L1 expression to guide immunotherapy decisions.

Being EGFR-negative does not close doors. It means the first question is answered and the search continues. Ask your oncologist what the next test in your workup will be.

Did you know?

EGFR mutations are found in Indian patients with lung adenocarcinoma at substantially higher rates than in Western populations — a consistent finding across data from ICMR and multiple Indian cancer centres.

This is why EGFR testing carries particular weight in Indian lung cancer care: the result is more likely to be actionable here than in most other parts of the world.

Source: Indian Council of Medical Research (ICMR); NCCN Guidelines for Non-Small Cell Lung Cancer

Explore 112 more Markers, Molecular Testing and Test Accuracy topics

HUB — How Accurate Is a Biopsy? Repeats, Errors and Second Opinions

HUB — IHC and Molecular Markers on a Biopsy

HUB — Labs, Slides and Second Opinions on a Biopsy

All Markers, Molecular Testing and Test Accuracy →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

Is EGFR testing the same as a hereditary cancer gene test?

No. EGFR testing looks for mutations that developed in your cancer cells — not mutations you were born with and could pass to your children. It is called somatic testing. The result guides treatment for your cancer and carries no implications for cancer risk in your family members. A hereditary cancer gene test, such as BRCA testing, is a separate test ordered for different reasons.

Can EGFR testing be done if my biopsy sample was small?

Sometimes a small sample is enough and sometimes it is not. The laboratory will advise after examining the tissue. If the sample is insufficient, a liquid biopsy from a blood draw is a recognised alternative. NCCN and ESMO both accept liquid biopsy when tissue cannot be obtained. Your oncologist can arrange this without requiring a new invasive procedure.

How long does EGFR testing take?

Results usually come back within one to two weeks of the sample reaching the laboratory. Delays can happen when the sample must go to a specialist centre or needs additional preparation. Ask your team when the sample was dispatched and when results are expected — knowing the date removes one source of uncertainty during an already difficult wait.

Is EGFR testing available at CION, and what does it cost?

EGFR testing is coordinated through CION's partner laboratory network. Costs vary between laboratories and are indicative — confirm the current figure with your treating centre. Testing is sometimes covered under government health schemes; ask your oncologist or the patient-support team whether you are eligible. Going untested means your oncologist cannot determine whether targeted therapy is an option, which is why it is worth exploring every avenue first.

My EGFR result is positive. Does that guarantee a response to targeted therapy?

A positive result means targeted therapy is the recommended first-line approach for your cancer, and response rates in EGFR-mutated non-small cell lung cancer are reported by ASCO and ESMO as substantially higher than with chemotherapy. It does not guarantee a response for every individual. Your oncologist will monitor you with scans and adjust the plan based on how your cancer actually behaves.

My cancer progressed on targeted therapy. Should EGFR testing be repeated?

Yes. When cancer progresses after EGFR-targeted therapy, it often does so through a new mutation — most commonly T790M. Repeat testing, on new tissue or a liquid biopsy, tells your team which mutation is driving the resistance and which treatment to consider next. This is part of standard care at progression, not an optional extra.

Full index

Browse all 701 biopsy topics

Every page in this section, grouped by the part of the journey it belongs to. Pick a group to see what is in it.

What Is a Biopsy?

What Is a Biopsy? Everything You Need to Know →

Types of Biopsy Compared

Which Biopsy Will You Have? Techniques Compared →

Preparing for a Biopsy

What to Expect on the Day of Your Biopsy →

Recovery and Aftercare

After a Biopsy: Recovery, Aftercare and Warning Signs →

Biopsy by Body Part

Biopsy by Body Part: What to Expect at Each Site →

Understanding Your Report

How to Read a Biopsy Report: Terms Explained →

IHC and Molecular Markers

IHC and Molecular Markers on a Biopsy: What They Mean →

Grading and Scoring Systems

Cytology & Prostate Scoring Systems Explained →

How Accurate Is a Biopsy?

How Accurate Is a Biopsy? Errors and Second Opinions →

If Your Result Is Benign

Your Biopsy Is Benign: What It Means and What Comes Next →

Call now Book free consultation